Most European patients would agree to change treatment to lower pain. Almost 82% stated they would accept rare adverse events in order to avoid invalidity, to benefit, if the risk of cancer was noted. There was a high agreement that a delay in treatment would be unsatisfactory for both familial and professional chores. **Conclusion:** There are regional differences in knowledge and perceptions about RA treatment. Romanian patients know less on T2T algorithm. Improving awareness of the T2T strategy among RA patients may need different types of support depending on the patient’s place of residence.

References:

Disclosure of Interests: CLAUDIA COBILINSCHI Speakers bureau: novartis, Mara Danila Speakers bureau: as personally stated, Daniela Oprea-Belisieni Speakers bureau: as declared, Ioana Saulescu Speakers bureau: Eli-Lilly, Pfizer, Laura Groseau Speakers bureau: novartis, Eli-liil, ucb, pfizer,sandoz, Sanziana Daia-ilieescu Speakers bureau: sandoz, Catalin Codreanu Consultant of: Speaker and consulting fees from AbbVie, Accord Healthcare, Alfasigma, Egis, Eli Lilly, Ewopharma, Genetics, Mylan, Novartis, Pfizer, Roche, Sandoz, UCBS, Speakers bureau: Speaker and consulting fees from AbbVie, Accord Healthcare, Alfasigma, Egis, Eli Lilly, Ewopharma, Genetics, Mylan, Novartis, Pfizer, Roche, Sandoz, UCBS, Razvan Ionescu Speakers bureau: as personally stated, Magdita Parva Consultant of: Speaker fee and consultant: Pfizer, Novartis, Roche, Abbvie, UCB. Eli-Lilly, Speakers bureau: Speaker fee and consultant: Pfizer, Novartis, Roche, Abbvie, UCB, Eli-Lilly, Horatui Popovicu Speakers bureau: as personally stated, CODRINA ANCUTA Consultant of: AbbVie, Pfizer, Roche, Novartis, UCB, Ewopharma, Merck Sharpe and Dohme, and Eli Lilly, Speakers bureau: AbbVie, Pfizer, Roche, Novartis, UCB, Ewopharma, Merck Sharpe and Dohme, and Eli Lilly, Elena Rezus: None declared, Claudia Mihai Adouk Speakers bureau: as personally stated, Ruxandra Ionescu Consultant of: Consulting fees from AbbVie, Eli-Lilly, Novartis, Roche, Sandoz, Speakers bureau: Consulting and speaker fees from AbbVie, Eli-Lilly, Novartis, Pfizer, Roche, Sandoz

DOI: 10.1136/annrheumdis-2020-eular.4744

---

**AB1270**

**RHEUMATOLOGY WORKFORCE IN LATIN AMERICA: TRAINING AND CURRENT STATUS**

D. G. Fernández-Avilá, D. Patino-Hernández1, S. Kowalski1, A. Vargas-Caselles1, A. M. Sapag Durán1, A. Cachafeiro Vilar1, B. Meléndez1, C. Silva1, E. Soriano1, D. Arrieta1, G. Reyes1, J. Then1, M. F. Ugarte-Gil1, M. Cardiel1

**Background:** The demand for rheumatology care has been steadily increasing over the last few years. However, supply seems to be insufficient, according to previous research. This situation may be at least partly explained by less physicians beginning a rheumatology residency program.

**Objectives:** We aim to identify baseline data, room for change, and to strengthen functional processes associated with the rheumatology workforce in order to improve care offered to patients living with rheumatic diseases.

**Methods:** Descriptive cross-sectional study. We obtained data on each country through local PANLR rheumatologists. They completed an online survey using the RedCap® platform, used for capture and storage of data. The sample was described according to the type of variable.

**Results:** 19 Latin American countries were included in this study, globally 1 rheumatologist was available per 106,838 inhabitants. The highest rates were found in Uruguay (1 per 23,695 inhabitants) and Argentina (1 per 40,384 inhabitants). The lowest rates were found in Nicaragua (1 per 640,648 inhabitants) and Guatemala (1 per 559,902 inhabitants). The ratio between women and men rheumatologists was 0.99 women per each man. The lowest proportions were found in Peru (0.261), and the highest in the Dominican Republic (2.5:1). The average age at the time of training was 51.1 (±12.75). The lowest average ages were found in Paraguay (41.3±10.77) and the highest age range were found in Peru (56.23±12.93). The average monthly compensation was USD $2,382.5 (±SD $1,462.5). Venezuela had the lowest salary (197), the highest salary was found in Costa Rica ($4,500). The proportion of rheumatologists trained abroad was 26.7%, ranging between 0% in Uruguay and 90% in Bolivia.

The countries with more rheumatology training programs were Brazil n = 50 and Mexico n = 20, while Ecuador, Honduras and Nicaragua don’t have any. The countries with the greatest amount of active residents were Brazil (n = 232) and Argentina (n = 100). The educational level required to enter the program was postgraduate studies in internal medicine in 42.11% of the programs. Currently, 108 residency programs in Latin America are active. Duration of residency programs is variable: 2 years (79.63% of cases), 3 years, (16.67%), 4 years (1.85%), 5 years (0.96%) or 6 years (0.96%). The median monthly compensation for residents was $ 528 USD (IQR $ 774), the country with the highest payment was Costa Rica ($ 2637). Contrarily, in Cuba, Chile and Colombia there is no payment to residents. Finally, in 8 countries (42.11%) residents must not pay for their postgraduate studies. The average annual tuition expense in the rest of countries is $ 1548 (SD $ 2749).

**References:**

**Disclosure of Interests:** Daniel G. Fernández-Avilá: None declared, Daniela Patino-Hernández: None declared, Sergio Kowalski: None declared, Alfredo Vargas-Caselles: None declared, Ana Maria Sapag Durán: None declared, Antonio Cachafeiro Vilar: None declared, Belia Meléndez: None declared, Carlos Santiago Paz: None declared, Carolina Cardiel: None declared, Claudia Mihai Adouk: None declared, Diana Fernández-Avilá: None declared, Ruxandra Ionescu: None declared, G. Reyes: None declared, Naielli Colman: None declared, Manuel F. Ugarth-Gil Grant/research support from: Janssen, Pfizer, Mario Cardiel: None declared, Nicola Rezus: None declared, Alba M. Sapag: None declared, Paula Burgos: None declared, Ruben Montufar: None declared, S documentaries: None declared, Yuri Las Fuentes-Silva: None declared, Enrique Soriano Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Cordis, Consultant of: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Speakers bureau: AbbVie, Amber, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer Inc, Roche

DOI: 10.1136/annrheumdis-2020-eular.2353

---

**AB1271**

**PATIENT EDUCATION IN PSORIATIC ARTHRITIS: A SERVICE EVALUATION AT ONE YEAR**

K. Austin1, R. Prasad1, 1University Hospitals Bristol NHS Foundation Trust, Rheumatology, Bristol, United Kingdom

**Background:** Recent studies have demonstrated an increasing burden of musculoskeletal (MSK) diseases worldwide. The importance of patient education (PE) is often overlooked in the management of long term inflammatory conditions. The European League Against Rheumatism recommends that PE should be integral to standard of care in inflammatory arthritis. PE increases patients knowledge, skills and confidence in managing their condition and improves patient activation (PA). Evidence shows that improved PA results in better outcomes and improved experiences of care. We previously reported on improved knowledge and confidence amongst a small patient group with psoriatic arthritis (PsA) who had attended a pilot education session. This education session was delivered to a wider group of patients with PsA over a 12 month period; we report on the evaluation received from this service.

**Objective:** To provide a framework to a wider group of patients with PsA, using a multi-disciplinary team (MDT) approach and to evaluate whether this improved patients’ knowledge, skills and confidence in managing their PsA.

**Methods:** Adult patients with PsA attending their rheumatology clinic appointments were invited to a 2.5 hour MDT education session which covered: 1) a general overview of PsA; 2) medications used in PsA; 3) the role of physiotherapy and occupational therapy; 4) flares and self-management. These were interactive sessions, held in a small group setting to allow for informal discussion and questions to the MDT. Written materials including several booklets and online resources were also provided. Patients evaluated their knowledge or understanding before and after each topic covered, on the same day, using an evaluation tool with 10 Likert scale items. Changes in ratings were analysed using student’s t-tests. Patients were also asked: which aspects they found particularly helpful, if there was anything they would like to have added/ have more of in the session; whether they found the session helpful; whether they would recommend...